Director Mark Froimson filed a Form 4 with the SEC on November 17, 2026, disclosing the disposition of all directly held common stock, restricted stock units, and stock options in Pacira BioSciences, Inc. following the consummation of a cash merger with Viatris Inc.

Key Highlights

  • Merger completed November 17, 2026: Peach Purchaser Sub Inc. merged with and into Pacira BioSciences, with Pacira continuing as a wholly owned subsidiary of Viatris Inc.
  • Offer price of $36.50 per share: Each share of Pacira common stock was converted into the right to receive $36.50, net of applicable withholding taxes and without interest.
  • 20,136 shares disposed (Transaction Code U): Froimson's 20,136 shares were disposed of pursuant to the tender offer at $36.50 per share, leaving 6,405 shares.
  • 6,405 RSU shares canceled (Transaction Code D): The remaining 6,405 shares, representing RSU settlements, were canceled at the Effective Time and converted into the right to receive the Offer Price in cash.
  • Nine stock options canceled: All outstanding stock options held by Froimson were canceled at the Effective Time; options with exercise prices above $36.50 were canceled with no consideration payable.
  • Beneficial ownership reduced to zero: Following all reported transactions, Froimson holds 0 shares of Pacira common stock directly.

Mark Froimson's Holdings Eliminated as Pacira-Viatris Merger Takes Effect

According to the filing, the transactions reported stem from the Agreement and Plan of Merger dated October 8, 2026, by and among Pacira BioSciences, Inc., Viatris Inc., and Peach Purchaser Sub Inc. On November 17, 2026, the Effective Time of the Merger, Purchaser completed a cash tender offer for all outstanding shares of Pacira common stock at $36.50 per share, net of applicable withholding taxes and without interest. Purchaser then merged with and into Pacira, with Pacira surviving as a wholly owned subsidiary of Viatris.

The filing discloses that director Mark Froimson disposed of 20,136 shares via Transaction Code U at $36.50, reducing his direct holdings to 6,405 shares. Those 6,405 shares, attributable to restricted stock unit awards, were then canceled and converted into the right to receive a cash amount equal to the number of shares issuable under each RSU multiplied by the Offer Price, subject to applicable tax withholdings. Following that cancellation, Froimson's direct beneficial ownership in common stock stands at zero, according to the filing.

In addition, the filing reports the cancellation of nine stock option awards with exercise prices ranging from $23.42 to $60.96 per share and covering a combined 80,247 shares. Per the filing, each option with an exercise price below $36.50 was canceled in exchange for a cash payment equal to the difference between the Offer Price and the exercise price, multiplied by the number of shares subject to that option, subject to applicable tax withholdings. Options with exercise prices at or above the Offer Price were canceled with no consideration payable. All nine option positions are reported as zero following the Merger. The filing was signed by Kristen Williams as Attorney-in-Fact on November 17, 2026. Pacira BioSciences is listed on NASDAQ:PCRX.

What Was Disclosed

Mark Froimson, a director of Pacira BioSciences, disclosed the elimination of all his direct holdings in the company's common stock, RSUs, and stock options on November 17, 2026, as a result of the cash merger between Pacira and Viatris Inc. at $36.50 per share.